Dimerix Advances with FDA Approval and New Licensing Deal

Dimerix Limited ( (AU:DXB) ) has provided an announcement.

Dimerix Limited announced significant progress in its quarterly activities report, highlighting a positive meeting with the FDA that confirmed proteinuria as an acceptable endpoint for marketing approval of DMX-200 in the US. The company also secured a development and license agreement with Fuso Pharmaceutical Industries for DMX-200 in Japan, potentially worth up to ¥10.5 billion, and continued to receive strong partnering interest globally. These developments, alongside its inclusion in the S&P ASX All Ordinaries, position Dimerix favorably in the biopharmaceutical industry, with potential implications for stakeholders through expanded market reach and financial growth.

More about Dimerix Limited

Dimerix Limited is a biopharmaceutical company focused on developing innovative therapies for unmet medical needs, particularly in the area of kidney disease. The company is headquartered in Fitzroy, Victoria, Australia, and is actively involved in advancing its Phase 3 clinical asset, DMX-200, for the treatment of focal segmental glomerulosclerosis (FSGS).

YTD Price Performance: 41.18%

Average Trading Volume: 1,602,835

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$268.5M

See more insights into DXB stock on TipRanks’ Stock Analysis page.